Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 16/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144833 | 0.90 | ALOX15 (0.49) | P2RY12USP30 | |
| SCHEMBL10144874 | 0.88 | HDAC6 (0.50) | P2RY12USP30 | |
| SCHEMBL10144834 | 0.80 | HPGDS (0.44) | USP30 | |
| SCHEMBL14018303 | 0.76 | HRH3 (0.56) | P2RY12USP30 | |
| SCHEMBL20460359 | 0.75 | ALOX15 (0.63) | — | |
| SCHEMBL20460316 | 0.75 | ALOX15 (0.63) | — | |
| SCHEMBL16812021 | 0.73 | SMO (0.69) | P2RY12USP30 | |
| SCHEMBL6140015 | 0.73 | CKS1B (0.56) | P2RY12USP30 | |
| SCHEMBL1908716 | 0.72 | USP30 (0.54) | P2RY12USP30 | |
| SCHEMBL6584014 | 0.71 | KMT2A (0.75) | P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394831-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394831-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-16 | — | — | US | disclosed |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-16 | — | — | US | disclosed |
| US-8071615-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071615-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2009-02-12 | — | — | US | disclosed |
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2009-02-12 | — | — | US | disclosed |
| US-7446109-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-04 | — | — | US | disclosed |
| US-7446109-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | P2RY12 4811/4885USP30 964/4885 |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | P2RY12 4811/4885USP30 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.